Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > My my!…The entire basher team is working overtime tonight!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(67)
•••
Comment by Quentin30on Apr 11, 2024 8:42pm
75 Views
Post# 35984611

RE:My my!…The entire basher team is working overtime tonight!

RE:My my!…The entire basher team is working overtime tonight!Peladawn...  only a Sith deals in extremes..!!

I suppose the earth is flat and the moon landings faked...  which kinda begs the question... if they faked the moon landing... why did they keep going back and faking them again and again... to make the fake a bit more believable than the last one..???

LOL

Besides your conspiracy theories to anyone with a view counter to your rose tinted opinion of ONCY, what DO you actually contribute here ?

HOW much can ONCY make from Pela + Pax do you think..? Have you actually done any math on this...?  Do you have any new and original thought, or just spout a rather tepid version of everything your pumper crew tells you to believe...

still, by the end of Q1, we'll start to have a REAL idea of how much this trial is gonna cost... how long it will take... and then Matt and Co can earn their salaries for once and tell us WHO is gonna pay for it all...

GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities